Boston Scientific Co. (NYSE:BSX) Shares Sold by Private Wealth Partners LLC

Private Wealth Partners LLC decreased its stake in Boston Scientific Co. (NYSE:BSX - Free Report) by 1.7% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 228,316 shares of the medical equipment provider's stock after selling 3,895 shares during the quarter. Boston Scientific comprises 1.6% of Private Wealth Partners LLC's portfolio, making the stock its 20th biggest holding. Private Wealth Partners LLC's holdings in Boston Scientific were worth $20,393,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of the business. TKG Advisors LLC boosted its holdings in Boston Scientific by 100.0% during the 4th quarter. TKG Advisors LLC now owns 52,016 shares of the medical equipment provider's stock valued at $4,646,000 after acquiring an additional 26,005 shares during the period. Convergence Investment Partners LLC bought a new position in shares of Boston Scientific in the 4th quarter worth $209,000. Plan Group Financial LLC raised its position in shares of Boston Scientific by 3.4% in the 4th quarter. Plan Group Financial LLC now owns 4,379 shares of the medical equipment provider's stock worth $391,000 after acquiring an additional 142 shares in the last quarter. Kentucky Retirement Systems Insurance Trust Fund raised its position in shares of Boston Scientific by 8.4% in the 4th quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 47,284 shares of the medical equipment provider's stock worth $4,223,000 after acquiring an additional 3,683 shares in the last quarter. Finally, Kestra Investment Management LLC bought a new position in shares of Boston Scientific in the 4th quarter worth $49,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

Several research analysts have recently commented on BSX shares. Raymond James boosted their price target on Boston Scientific from $119.00 to $122.00 and gave the stock a "strong-buy" rating in a research report on Thursday, February 6th. Morgan Stanley boosted their price target on Boston Scientific from $100.00 to $120.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Wells Fargo & Company boosted their target price on Boston Scientific from $100.00 to $118.00 and gave the stock an "overweight" rating in a research note on Thursday, February 6th. StockNews.com downgraded Boston Scientific from a "buy" rating to a "hold" rating in a research note on Thursday. Finally, UBS Group boosted their target price on Boston Scientific from $105.00 to $130.00 and gave the stock a "buy" rating in a research note on Friday, February 7th. Two equities research analysts have rated the stock with a hold rating, twenty-one have assigned a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $107.39.

Insider Transactions at Boston Scientific

In related news, CFO Daniel J. Brennan sold 67,333 shares of the company's stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $105.24, for a total value of $7,086,124.92. Following the completion of the transaction, the chief financial officer now owns 225,808 shares of the company's stock, valued at approximately $23,764,033.92. This represents a 22.97 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Arthur C. Butcher sold 14,010 shares of the company's stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the transaction, the executive vice president now directly owns 978 shares of the company's stock, valued at $87,306.06. The trade was a 93.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 153,640 shares of company stock worth $15,718,289 over the last quarter. 0.50% of the stock is currently owned by insiders.

Boston Scientific Stock Performance

Shares of BSX traded down $0.96 during mid-day trading on Friday, reaching $104.40. The company had a trading volume of 3,475,630 shares, compared to its average volume of 5,967,317. Boston Scientific Co. has a 52-week low of $65.52 and a 52-week high of $107.17. The company has a quick ratio of 1.02, a current ratio of 1.08 and a debt-to-equity ratio of 0.41. The stock has a market capitalization of $154.07 billion, a P/E ratio of 83.62, a PEG ratio of 2.79 and a beta of 0.80. The stock has a 50 day moving average of $97.69 and a two-hundred day moving average of $89.06.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, topping analysts' consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, analysts expect that Boston Scientific Co. will post 2.85 earnings per share for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.